News

Head of Bioneer:FARMA, Dr. Anette Müllertz, gave a talk with the topic "Vision for Now and the Future: Preclinical Development Utilizing Biopharmaceutics and QbD Principles can Guide, Support, and Optimize in vivo Drug Performance" at a FDA-sponsored meeting in June at the University of Wisconsin. The meeting was one of multiple meetings aiming to implement FDA's new initiative on "Quality by Design" (QbD) in the drug development process. See the meeting report here: http://www.dissolutiontech.com/DTresour/200911Articles/DT200911_A06.pdf